title: Using canine osteosarcoma as a model to assess efficacy of novel therapies: can old dogs teach us new tricks?
abstract: Since its domestication more than 10,000 years ago, the dog has been the animal that most intimately shares our work and homelife. Interestingly, the dog also shares many of our diseases including cancer such as osteosarcoma. Like the human, osteosarcoma is the most common bone malignancy of the dog and death from pulmonary metastasis is the most common outcome. The incidence of this spontaneous bone neoplasm occurs ten times more frequently that it does so in children with about 8,000-10,000 cases estimated to occur in dogs in the USA. Because there is no "standard of care" in veterinary medicine, the dog can also serve us by being a model for this disease in children. Although the most common therapy for the dog with osteosarcoma is amputation followed by chemotherapy, not all owners choose this route. Consequently, novel therapeutic interventions can be attempted in the dog with or without chemotherapy that could not be done in humans with osteosarcoma due to ethical concerns. This chapter will focus on the novel therapies in the dog that have been reported or are in veterinary clinical trials at the author's institution. It is hoped that collaboration between veterinary oncologists and pediatric oncologists will lead to the development of novel therapies for (micro- or macro-) metastatic osteosarcoma that improve survival and might ultimately lead to a cure in both species.
authors.affiliation: Department of Veterinary Surgical and Radiological Sciences, William R. Pritchard Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis, CA, USA, dvmrodriguez@ucdavis.edu.
authors.forename: Carlos O
authors.initials: CO
authors.lastname: Rodriguez
mesh_terms: D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives / Q000494:pharmacology; D000336:Aerosols; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D002648:Child; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D004283:Dog Diseases; D004285:Dogs; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000662:veterinary*; D008982:Molybdenum / Q000494:pharmacology; D012516:Osteosarcoma / Q000188:drug therapy / Q000556:secondary / Q000662:veterinary*; D010714:Phosphatidylethanolamines / Q000494:pharmacology; D015398:Signal Transduction; D000093542:Gemcitabine
chemical_list: D000336:Aerosols; D000970:Antineoplastic Agents; D007376:Interleukin-2; D010714:Phosphatidylethanolamines; D003841:Deoxycytidine; C037144:mifamurtide; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D008982:Molybdenum; C020809:tetrathiomolybdate; D000093542:Gemcitabine